Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs11.29 B15.23 B18.42 B19.22 B19.98 B19.93 B—Recherche et développement5.99 B9.74 B9.76 B10.94 B13.58 B14.23 B—Résultat d'exploitation5.16 B1.06 B3.76 B8.19 B10 B13.74 B—Total des produits hors exploitation———————Charges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts———————Revenus/dépenses exceptionnels———————Résultat avant impôts3.92 B265 M2.5 B6.9 B8.69 B12.4 B—Part des actionnaires dans le résultat———————Impôts772 M380 M792 M938 M1.65 B2.17 B—Intérêts ne donnant pas le contrôle / intérêts minoritaires52 M3 M5 M6 M6 M8 M—Autres produits/charges après impôts———————Résultat net avant activités abandonnées3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Activités abandonnées———————Résultat net3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Ajustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires———————Bénéfice par action de base (BPA de base)———————Bénéfice par action dilué (BPA dilué)———————Nombre moyen d'actions de base en circulation———————Nombre d'actions en circulation après dilution———————EBITDA———————EBIT———————Coût des ventes5.3 B12.44 B12.39 B8.27 B10.21 B10.63 B—Autres coûts des ventes———————Amortissements (flux de trésorerie)———————
AstraZeneca PLC - American Depositary Shares
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje.